Let us pause and savour this exquisite irony. The United States, that self-appointed beacon of pharmaceutical innovation, home to the world’s most prestigious medical research institutions, is being humiliated by a drug discount that would make a Victorian pawnbroker blush. Canadian Ozempic, the diabetes wonder-drug that has become the darling of Hollywood weight loss, costs half of what Americans pay. The explanation? Canada’s drug pricing board, a drab bureaucratic contraption that our libertarian cousins would instinctively despise, simply says 'no' to the manufacturers. The NHS procurement model, that much-maligned paragon of socialist mediocrity, achieves the same result with the quiet dignity of a librarian.
The American system, by contrast, operates on a feudal logic: patients are serfs to the patent-holders, and the pharmacy benefit managers are the lords who extract their tithes. The result is a grotesque patchwork of middlemen, rebates, and opaque pricing that would make a Venetian merchant of the fifteenth century blush. We have watched for decades as US politicians sermonize about free markets while their constituents pay four times the European price for insulin. The Canadian revelation is merely the latest chapter in a long saga of transatlantic healthcare humiliation.
But the deeper lesson here is about procurement. The NHS, despite its perpetual crises and ambulance queues, has mastered the art of the counter-offer. It does not negotiate with desperation; it negotiates with volume. Eight hundred thousand Canadians might not sound impressive, but when combined with the UK’s sixty-six million, the negotiating muscle is formidable. This is the same principle that allowed the East India Company to dictate terms to Indian weavers. Scale confers power.
Yet the American body politic recoils from such a model as if from a leper. Why? Because it would require admitting that healthcare is not a luxury good but a public utility. It would mean acknowledging that the profit motive, when applied to human suffering, produces more suffering than profit. The Canadian pricing model is not radical; it is merely rational. It is a quiet rebuke to the American gospel of market absolutism.
And let us not forget the cultural dimension. The US loves to caricature Canada as a bland, polite, and slightly boring appendage. But when it comes to drug pricing, the Canadians have shown they possess something the Americans have lost: the courage to tell a global corporation that its price is unacceptable. That is not politeness; that is spine. The NHS, for all its flaws, has the same backbone. The American system, by contrast, has the spine of a jellyfish.
So here is the verdict: the Canadian Ozempic victory is not a story about Canada. It is a story about American failure. It is a case study in how intellectual decadence and regulatory capture have poisoned the well of American healthcare. The NHS procurement model, dismissed by many as a bureaucratic dinosaur, has proven to be the superior predator.
Perhaps it is time for the Americans to swallow their pride and learn from their northern neighbours. After all, history is replete with empires that refused to adapt and paid the price. The question is not whether the US will eventually adopt a more rational drug pricing system. The question is how many lives will be sacrificed before it does.
